Richemont Q1 Sales Beat Forecast as Cartier Demand Drives Strong Growth 
Paramount-Warner Bros. Discovery Merger Faces Lawsuit From 12 States 
Volkswagen Launches €28,000 ID. Cross EV as Europe’s Electric Vehicle Demand Accelerates 
Apple Intelligence Cleared for China as Alibaba and Baidu AI Power iPhone Features 
Nvidia Partners With Fanuc and Yaskawa to Accelerate AI Robotics in Japan 
DeepSeek Eyes China IPO as AI Startup Seeks $71 Billion Valuation in New Funding Round 
BHP Q4 Iron Ore Output Rebounds as Copper Prices Boost Revenue 
United Airlines Beats Q2 Earnings, Raises 2026 Profit Outlook Despite Higher Fuel Costs 
Uber to Acquire Delivery Hero in $14.8 Billion Deal to Expand Global Food Delivery Business 
Eli Lilly Eyes AtaiBeckley Acquisition to Expand Psychedelic Mental Health Pipeline 
NY Times Challenges Trump Administration Subpoenas Over Air Force One Report 
Alibaba Stock Jumps as China Approves Apple Intelligence Powered by Qwen AI 
xAI Sues Man for Allegedly Using Grok to Generate AI Child Abuse Deepfakes 
ASML Raises 2026 Outlook as AI Chip Demand Lifts Q2 Earnings 
Sodexo Unveils Shift & Grow 2030 Strategy, Targets Over 5% Revenue Growth by Fiscal 2030 
SK Hynix Stock Soars as AI Memory Demand Outlook Fuels Chip Rally 
UBS Boosts China Tech Bets, Adds Kuaishou and Meituan to Focus List 
NEW YORK, Feb. 01, 2016 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Esperion Therapeutics, Inc. (“Esperion”) (NASDAQ:ESPR) between August 18, 2015 and September 28, 2015.
You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the Eastern District of Michigan. To get more information go to: http://zlk.9nl.com/esperion-espr.
The complaint alleges that Defendants issued false and misleading statements regarding the Company’s business and prospects, including that there was no clear path to approval for ETC-1002, the Company’s lead product candidate designed to lower LDL-cholesterol levels, and that the FDA had encouraged the Company to initiate a cardiovascular outcomes trial (“CVOT”) and that completion of a CVOT could be necessary prior to approval of ETC-1002.
On August 17, 2015, Esperion reported to investors material events from an August 2015 meeting with the FDA; the Company stated that during the meeting it was informed by the FDA that the Company would not have to complete a CVOT to gain approval of ETC-1002. Then in a September 28, 2015 news release the Company noted that the FDA had actually “encouraged the Company to initiate a cardiovascular outcomes trial promptly” and it may be necessary to have a completed CVOT prior to approval.
If you suffered a loss in Esperion you have until March 14, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/esperion-espr.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Eduard Korsinsky, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
